Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

35.74USD
19 Jan 2017
Change (% chg)

$-0.30 (-0.83%)
Prev Close
$36.04
Open
$35.72
Day's High
$35.83
Day's Low
$35.66
Volume
557,017
Avg. Vol
3,883,753
52-wk High
$57.81
52-wk Low
$30.89

Select another date:

Thu, Jan 12 2017

Photo

Novo Nordisk shares hit by U.S. lawsuit, Trump comments

COPENHAGEN Danish drugmaker Novo Nordisk's shares fell more than 5 percent on Thursday following the filing of a lawsuit against the company in the United States and also in response to U.S. President-elect Donald Trump's criticism of drug prices.

UPDATE 1-Novo Nordisk shares hit by US lawsuit, Trump comments

* Novo shares down 5.4 pct while Europe drug stocks down 2 pct (Adds comments from Novo Nordisk, Trump and analyst, details)

U.S. law firm files class action suit against Novo Nordisk

COPENHAGEN, Jan 12 A U.S. law firm has filed a securities class action lawsuit on behalf of Lehigh County Employees' Retirement System against Danish drugmaker Novo Nordisk.

BRIEF-Novo Nordisk's Fiasp approved in Europe

* The European Commission has granted marketing authorisation for Fiasp (fast-acting insulin aspart) for treatment of diabetes in adults

Sanofi sues Novo Nordisk over diabetes drugs in the U.S.

France's Sanofi has filed a lawsuit in the United States accusing Novo Nordisk of falsely claiming that Sanofi insulin drugs would no longer be available for many U.S. patients so it could promote its competing drug.

Novo Nordisk seeks EU and U.S. approval for new diabetes treatment

OSLO Danish Novo Nordisk said on Monday it has filed for the European Union and the U.S. approval of semaglutide to treat adults with type 2 diabetes.

Novo Nordisk reports Tresiba insulin achieves target in study

COPENHAGEN Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile and reduces episodes of severely low blood glucose levels in patients with type 2 diabetes, the Denmark-based company said on Tuesday.

UPDATE 1-Novo Nordisk reports Tresiba insulin achieves target in study

COPENHAGEN, Nov 29 Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile and reduces episodes of severely low blood glucose levels in patients with type 2 diabetes, the Denmark-based company said on Tuesday.

Novo Nordisk says Tresiba insulin achieves target in DEVOTE study

COPENHAGEN, Nov 29 Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile in patients with type 2 diabetes, results released by the company on Tuesday showed.

UPDATE 1-TDC loses major contract with Novo Nordisk to Telenor

COPENHAGEN, Nov 29 Danish telecoms group TDC has lost a major contract in Denmark after one of the country's biggest employers, Novo Nordisk, said it chose Norway's Telenor as its telecoms supplier.

Select another date: